Document is current
Any future updates will be listed below
-
Authors
Friedman, Claire F https://orcid.org/0000-0003-2621-8553
Spencer, Christine
Cabanski, Christopher R
Panageas, Katherine S
Wells, Daniel K
Ribas, Antoni
Tawbi, Hussein https://orcid.org/0000-0003-1942-851X
Tsai, Katy
Postow, Michael https://orcid.org/0000-0002-3367-7961
Shoushtari, Alexander https://orcid.org/0000-0002-8065-4412
Chapman, Paul https://orcid.org/0000-0003-1618-0811
Karakunnel, Joyson
Bucktrout, Samantha
Gherardini, Pier
Hollmann, Travis J
Chen, Richard O
Callahan, Margaret
LaVallee, Theresa
Ibrahim, Ramy
Wolchok, Jedd
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02731729 at ClinicalTrials.govnct03033576 at ClinicalTrials.govDocuments that mention this clinical trial
305 Technical considerations for normalizing digital spatial profiling data with multiple within-patient samples
https://doi.org/10.1136/jitc-2020-sitc2020.0305
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
https://doi.org/10.1136/jitc-2021-003853
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
https://doi.org/10.1136/jitc-2023-007309
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
https://doi.org/10.1136/jitc-2021-003853
-
Funding
Funding for this research was provided by:
Bristol Myers-Squibb
Cancer Center (P30 CA008748)
Parker Institute for Cancer Immunotherapy
- License Information
